Stefano Tarantolo

5.5k total citations · 1 hit paper
79 papers, 3.3k citations indexed

About

Stefano Tarantolo is a scholar working on Hematology, Oncology and Immunology. According to data from OpenAlex, Stefano Tarantolo has authored 79 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Hematology, 33 papers in Oncology and 21 papers in Immunology. Recurrent topics in Stefano Tarantolo's work include Hematopoietic Stem Cell Transplantation (27 papers), Neutropenia and Cancer Infections (11 papers) and Acute Myeloid Leukemia Research (10 papers). Stefano Tarantolo is often cited by papers focused on Hematopoietic Stem Cell Transplantation (27 papers), Neutropenia and Cancer Infections (11 papers) and Acute Myeloid Leukemia Research (10 papers). Stefano Tarantolo collaborates with scholars based in United States, Canada and Germany. Stefano Tarantolo's co-authors include Vijay Reddy, Hildegard Greinix, Pranatharthi Chandrasekar, Lisa D. Pedicone, Andrew J. Ullmann, Navdeep Boparai, Jeffrey H. Lipton, Amelia Langston, Hernando Patino and David H. Vesole and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Stefano Tarantolo

78 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host Disease

2007 930 citations Stefano Tarantolo et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stefano Tarantolo United States	24	1.1k	1.1k	958	918	551	79	3.3k
A. G. Prentice United Kingdom	29	968 0.9×	622 0.6×	631 0.7×	637 0.7×	749 1.4×	68	3.3k
Dick Stockelberg Sweden	22	1.7k 1.5×	1.2k 1.1×	1.1k 1.2×	763 0.8×	151 0.3×	66	3.6k
Michael Kiehl Germany	34	1.4k 1.3×	793 0.7×	462 0.5×	907 1.0×	774 1.4×	87	3.6k
Chantal Doyen Belgium	23	1.5k 1.4×	811 0.8×	656 0.7×	1.8k 1.9×	225 0.4×	74	3.6k
Hartmut Link Germany	36	2.4k 2.2×	835 0.8×	439 0.5×	1.9k 2.1×	501 0.9×	142	5.1k
Ashley Vo United States	40	703 0.6×	759 0.7×	459 0.5×	592 0.6×	1.8k 3.3×	129	5.7k
Gerlinde Egerer Germany	41	1.2k 1.1×	927 0.9×	677 0.7×	1.4k 1.5×	194 0.4×	181	4.6k
Yves Chalandon Switzerland	34	2.3k 2.0×	728 0.7×	321 0.3×	995 1.1×	761 1.4×	192	4.3k
Joseph Kapelushnik Israel	31	1.2k 1.1×	389 0.4×	242 0.3×	495 0.5×	592 1.1×	128	3.1k
Sharon K. Gershon United States	8	544 0.5×	1.5k 1.4×	1.4k 1.5×	281 0.3×	1.2k 2.2×	9	3.9k

Countries citing papers authored by Stefano Tarantolo

Since Specialization

Citations

This map shows the geographic impact of Stefano Tarantolo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stefano Tarantolo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stefano Tarantolo more than expected).

Fields of papers citing papers by Stefano Tarantolo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stefano Tarantolo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stefano Tarantolo. The network helps show where Stefano Tarantolo may publish in the future.

Co-authorship network of co-authors of Stefano Tarantolo

This figure shows the co-authorship network connecting the top 25 collaborators of Stefano Tarantolo. A scholar is included among the top collaborators of Stefano Tarantolo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stefano Tarantolo. Stefano Tarantolo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Budde, Lihua E., Don A. Stevens, Gary J. Schiller, et al.. (2024). Durable complete response and overall survival in patients with heavily pretreated, poor-prognosis non-Hodgkin lymphoma to immunoactivating AVM0703 with few and mild drug-related adverse effects.. Journal of Clinical Oncology. 42(16_suppl). 7077–7077.

Garcia‐Manero, Guillermo, David A. Sallman, Stefano Tarantolo, et al.. (2024). Preliminary Safety, Efficacy and Molecular Characterization in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Single Agent Emavusertib (CA-4948). Blood. 144(Supplement 1). 3225–3225. 2 indexed citations

Gopal, Ajay K., Stefano Tarantolo, Naresh Bellam, et al.. (2014). Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients. Investigational New Drugs. 32(6). 1213–1225. 19 indexed citations

Chakraborty, Subhankar, et al.. (2011). Progressive Multifocal Leukoencephalopathy in a HIV-Negative Patient with Small Lymphocytic Leukemia following Treatment with Rituximab. SHILAP Revista de lepidopterología. 4(1). 136–142. 9 indexed citations

Richardson, Paul G., Ashraf Badros, Sundar Jagannath, et al.. (2010). Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma. British Journal of Haematology. 150(4). 428–437. 58 indexed citations

Floreani, Anthony A., et al.. (2007). Novel C5a Agonist-Based Dendritic Cell Vaccine in a Murine Model of Melanoma. Cell Cycle. 6(22). 2835–2839. 13 indexed citations

Ganti, Apar Kishor, James D. Landmark, Anne Kessinger, Lynette M. Smith, & Stefano Tarantolo. (2006). Vincristine-laden platelet transfusion for patients with refractory thrombocytopenia.. PubMed. 20(4). 559–63. 2 indexed citations

Ganti, Apar Kishor, et al.. (2005). Successful hematopoietic stem‐cell transplantation in multicentric Castleman disease complicated by POEMS syndrome. American Journal of Hematology. 79(3). 206–210. 37 indexed citations

Demirkazık, Ahmet, Anne Kessinger, James Lynch, et al.. (2002). Effect of prior therapy and bone marrow metastases on progenitor cell content of blood stem cell harvests in breast cancer patients. Biology of Blood and Marrow Transplantation. 8(5). 268–272. 3 indexed citations

10.

Tarantolo, Stefano, et al.. (2001). Primary extramedullary plasmacytoma in the atria of the heart. Cardiovascular Pathology. 10(3). 137–139. 14 indexed citations

11.

Hauke, Ralph J., Bassam N. Smir, Timothy C. Greiner, et al.. (2001). Clinical and pathological features of posttransplant lymphoproliferative disorders: Influence on survival and response to treatment. Annals of Oncology. 12(6). 831–834. 18 indexed citations

12.

Gajewski, James, Michèle L. Donato, Sergio Giralt, et al.. (2000). Allogeneic stem cell transplantation (BMT) for AML and MDS following i.v. busulfan and cyclophosphamide (i.v. BuCy). Bone Marrow Transplantation. 25(S2). S35–S38. 34 indexed citations

13.

Mata, John E., Michael R. Bishop, Stefano Tarantolo, et al.. (2000). Evidence of Enhanced Iron Excretion During Systemic Phosphorothioate Oligodeoxynucleotide Treatment. Journal of Toxicology Clinical Toxicology. 38(4). 383–387. 13 indexed citations

14.

Chinnakotla, Srinath, et al.. (2000). CLOPIDOGREL-ASSOCIATED THROMBOTIC THROMBOCYTOPENIC PURPURA/HEMOLYTIC UREMIC SYNDROME IN A KIDNEY/PANCREAS TRANSPLANT RECIPIENT. Transplantation. 70(3). 550–552. 20 indexed citations

15.

Singh, Rakesh Kumar, et al.. (1998). IL-2 Expansion of T and NK Cells from Growth Factor-Mobilized Peripheral Blood Stem Cell Products. Journal of Immunotherapy. 21(6). 409–417. 10 indexed citations

16.

Bishop, Michael, Jonathan Jackson, Stefano Tarantolo, et al.. (1997). Ex Vivo Treatment of Bone Marrow with Phosphorothioate Oligonucleotide OL(l)p53 for Autologous Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndrome. Journal of Hematotherapy. 6(5). 441–446. 20 indexed citations

17.

Ino, Kazuhiko, et al.. (1997). Restoration of T and NK cell function in GM-CSF mobilized stem cell products from breast cancer patients by monocyte depletion. Bone Marrow Transplantation. 20(2). 117–123. 24 indexed citations

18.

Kessinger, Anne, Michael R. Bishop, JR Anderson, et al.. (1995). Comparison of Subcutaneous and Intravenous Administration of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor for Peripheral Blood Stem Cell Mobilization. Journal of Hematotherapy. 4(2). 81–84. 5 indexed citations

19.

Martín‐Algarra, Salvador, Michael R. Bishop, Stefano Tarantolo, et al.. (1995). Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.. Deposito Adademico Digital Universidad De Navarra (University of Navarra). 23(14). 1503–8. 16 indexed citations

20.

Darrington, Deborah L., Julie M. Vose, J R Anderson, et al.. (1994). Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies.. Journal of Clinical Oncology. 12(12). 2527–2534. 256 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact